• Twitter
  • LinkedIn
  • Facebook
ARK Investment Management
  • Solutions
    • Institutional Accounts
    • Separately Managed Accounts
    • Mutual Fund
    • Exchange-Traded Funds
  • Advisor Services
    • Strategies
    • Our Clients
  • Research
    • Blogs
    • Podcast
    • White Papers
    • Webinars
    • Newsletter
    • ARK Big Ideas 2019
  • About ARK
    • Philosophy
    • Investment Process
    • Team
    • In The News
  • Contact
  • Search
  • Menu
You are here: Home / Research / MRK
  • Social Networks, facebook, instagram, twitter, network effect, network research, ark invest

    Social Networks Unpacked – Six Charts That Explain the Rise of Facebook, Twitter, and Instagram

    July 07, 2015 | by James Wang, ARK Analyst | Digital
    Mentioned Companies: AIG, BMW, FB, IBM, LNKD, MRK, NKE, SBUX, TWTR

    The three most popular consumer social networks, Facebook , Twitter , and Instagram, have grown from scrappy upstarts to some of the most powerful communication platforms on earth. Despite the similarities of these platforms, users, celebrities, and companies are embracing them in different ways. To understand how they are evolving and performing, ARK researched engagement […]

  • biosimilars, biologics, generics, cost, pharma, ark genome, genomic revolution, ARKG, Ark invest.

    Biosimilars vs Generics: History Does Not Repeat, It Rhymes

    May 18, 2015 | by Erik Tvetenstrand, ARK Analyst | Health
    Mentioned Companies: AMGN, BIIB, CELG, ESRX, MRK, NVS, ORINY

    Healthcare investors likely remember the devastating impact of generic drugs on drug prices in the late 1980s. While traditional firms struggled, many successful biotechnology companies took root during this turbulent period. Focusing on the growing field of biologic medicine, many biotech firms were acquired by pharmaceutical companies looking to lower research and development costs, while […]

  • immunotherapy, ark research, health care research, invest in health care

    Immunotherapy: Unleashing the Immune System to Decimate Cancer

    April 10, 2015 | by James Bannon, ARK Analyst | Health
    Mentioned Companies: AMGN, BMY, JUNO, KITE, MRK, NVS

    For more than a century, surgery and poison have been the antidotes to cancer. When tumors are discovered, doctors decide whether or not to remove them surgically. With or without surgery, doctors typically prescribe chemotherapy in an attempt to eradicate the disease chemically. Immunotherapy is the most heralded cancer treatment of the last 20 years, offering […]

  • Curing Diabetes, stem cells, diabetes, cure, hypertension, obesity, harvard, cdc, genomic revolution, ARKG, arkgenome, ark, ark investment management, investing, ETFs

    Curing Diabetes with Stem Cells

    December 02, 2014 | by James Bannon, ARK Analyst | Health
    Mentioned Companies: LLY, MRK, NVO, SNY

    New research out of Harvard University’s Stem Cell Institute may have cracked the code to curing diabetes. In a break-through study, scientists were able to turn human embryonic stem cells into fully mature insulin-producing beta cells and implant them into living tissue. While currently only in animals, these studies, if successful in humans, could point […]

Subscribe to ARK Research

ARK’s Podcast On

ark podcast, fyi podast, for your innovation podcast, ark invest podcast, innovation podcast, investment podcast     ark podcast, fyi podast, for your innovation podcast, ark invest podcast, innovation podcast, investment podcast     ark podcast, ark disruptive innovation, fyi podcast, ark podcast     Image result for stitcher badge

New Call-to-action
 ARK Original Research

All original research is vetted through ARK’s research ecosystem and by its Director of Research. Every published article is reviewed by ARK’s CEO/CIO Catherine D. Wood.

Follow ARK on Twitter

Tweets by @ARKinvest

ADVISOR SERVICES

Strategies
Solutions
Thought Leadership
Our Clients

EXPLORE ARK ETFs

RESEARCH

Blogs
Podcast
White Papers
Webinars
Newsletter
Big Ideas 2019

ABOUT ARK

ARK Philosophy
ARK Process
ARK Team
Theme Developers
Board of Directors

CONTACT

FAQs
Press and Media
Job Opportunities

©2019, ARK Investment Management LLC (“ARK”). All content is original and has been researched and produced by ARK unless otherwise stated. No part of ARK’s original content may be reproduced in any form, or referred to in any other publication, without the express written permission of ARK. The content is available for informational purposes only and is subject to change without notice. All statements made regarding companies or securities or other financial information on this site or any sites relating to ARK are strictly beliefs and points of view held by ARK or the third party making such statement and are not endorsements by ARK of any company or security or recommendations by ARK to buy, sell or hold any security. For a list of all purchases and sales made by ARK for client accounts during the past year that could be considered by the SEC as recommendations, click here. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this list. For full disclosures, please see the Terms of Use for this site.
  • Privacy Policy
  • Terms of Use
  • PATENT
Scroll to top